DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026" drug pipelines to their offering.
The report "EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and global trends for GHD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex from 2016 to 2026.
The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD (COGHD) and adult onset GHD (AOGHD).
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.5 Epidemiological Forecast for GHD (2016-2026)
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xmnkrq/epicast_report